Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0X9WC
|
||||
| Former ID |
DIB006762
|
||||
| Drug Name |
ISIS-DMPK
|
||||
| Drug Type |
Antisense drug
|
||||
| Indication | Myotonic dystrophy [ICD10:G71.1] | Phase 1/2 | [1] | ||
| Target and Pathway | |||||
| Target(s) | mRNA of DMPK | Target Info | [2] | ||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02312011) A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1. U.S. National Institutes of Health. | ||||
| REF 2 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.